Researchers at Turku Bioscience in joint collaboration with the Örebro University, Sweden have uncovered new ‘metabolic signatures’ of human CD4+ T-cells
From left to right: Dr. Alex M Dickens*, Dr. Partho Sen*, Dr. Syed Bilal Ahmad Andrabi+ and Dr. Tanja Buchacher+. ‘*’ represents Systems Medicine group headed by Prof. Matej Orešič, and ‘+’ represents Molecular Systems Immunology group headed by Prof. Riitta Lahesmaa.
T-cells are white blood cells that coordinate our immune response and provide protection against pathogens and cancer. Abnormally functioning T cells may lead to the development of cancer or autoimmune disorders.
Scientists at University of Turku and Örebro University studied metabolism of human T cells with sophisticated, cutting edge technologies such as computer-based modelling, high throughput lipidomics, transcriptomics techniques, and conducting in vitro knockdown experiments. They identified that certain molecular lipids such as ceramides and glycosphingolipids play an important role in the functioning of human T cells.
Intriguingly, these lipids were found to be regulated differently in T cell subsets. Experimental manipulation of glycosphingolipid pathways altered the T-cell functions. Particularly, the expression of proinflammatory cytokines was affected in a subset of T-cells called Th17 cells, known to be associated with various immune-mediated disease such as autoimmune diseases, and cancer. In particular, the study identified serine palmitoyl transferase (SPT), as an important target for regulating the expression of proinflammatory cytokine (IL17A and IL17F) by Th17 cells. The authors say “ Our results provide basis for engineering and manipulating metabolism of human T-cells to treat immune-mediated diseases”.
Manipulating human T-cell metabolism to modulate their early specification for therapeutic purposes is a new paradigm and offers significant new options in the future to develop safe and effective therapies for cancer and autoimmune diseases. Since ceramides are lipotoxic lipids that are commonly elevated in obesity and insulin resistance, our study may also offer clues about the poorly understood overlap in co-morbidities between specific immune-mediated diseases characterized by expression of proinflammatory cytokines and metabolic diseases, such as has been found to occur in COVID19.
Article published in Cell Reports, titled as “Quantitative genome-scale metabolic modeling of human CD4+ T-cell differentiation reveals subset-specific regulation of glycosphingolipid pathways”. Link to article
Recent Posts
- Carlos Rogério Figueiredo received the Young Investigator Award Carlos Rogério Figueiredo has received the Young Investigator Award from the Scandinavian Society for Immunology. Read moreNovember 4, 2025
- Participate to Open Hardware Workshop, sign up now! Access to research hardware remains a global challenge and it impacts also researchers in high-income Read moreNovember 3, 2025
- The Academy of Finland granted Johanna Ivaska €2,400,000 in funding for an Academy Professor position The Academy of Finland granted our Group Leader, Professor Johanna Ivaska €2,400,000 in funding for Read moreOctober 30, 2025
- Guillaume Jacquemet and Cecilia Sahlgren receive funding for the Research Council of Finland Centre of Excellence in Immune-Endothelial Interactions (IMMENs) Associate Professor Guillaume Jacquemet, our Group Leader, and Professor Cecilia Sahlgren, our affiliated Group Leader, Read moreOctober 30, 2025
- Registration to AI2Med imaging event is now open! Registration for AI2Med Turku 2025 is open! The event is organized by the Turku PET Read moreOctober 21, 2025
- Jonna Alanko receives the Young Investigator Award from the Scandinavian Society for Immunology Jonna Alanko has received the Young Investigator Award of the Scandinavian Society for Immunology. The Read moreOctober 17, 2025